Lithium induces autophagy by inhibiting inositol monophosphatase

Journal of Cell Biology

Volumn 170, Issue 7, 2005, Pages 1101-1111

  Sarkar, Sovan ^a   Floto, R Andres ^b   Berger, Zdenek ^a,c   Imarisio, Sara ^a,c   Cordenier, Axelle ^a,c   Pasco, Matthieu ^c   Cook, Lynnette J ^a   Rubinsztein, David C ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ENZYME; GLYCOGEN SYNTHASE KINASE 3BETA; HUNTINGTIN; INOSITOL; INOSITOL 1,4,5 TRISPHOSPHATE; INOSITOL MONOPHOSPHATASE; LITHIUM; MAMMALIAN TARGET OF RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; DATA ANALYSIS; DOWNSTREAM PROCESSING; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; RAT;

ALPHA-SYNUCLEIN; ANIMALS; AUTOPHAGY; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME INHIBITORS; HUMANS; INOSITOL; LITHIUM; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN KINASES; SIROLIMUS;

MAMMALIA;

EID: 25444483066     PISSN: 00219525     EISSN: None     Source Type: Journal    
DOI: 10.1083/jcb.200504035     Document Type: Article

References (36)

1. Atack, J.R., S.M. Cook, A.P. Watt, S.R. Fletcher, and C.I. Ragan. 1993. In vitro and in vivo inhibition of inositol monophosphatase by the bisphosphonate L-690,330. J. Neurochem. 60:652-658.
2. Berridge, M.J., C.P. Downes, and M.R. Hanley. 1989. Neural and developmental actions of lithium: a unifying hypothesis. Cell. 59:411-419.
3. Camus, M., G. Hennere, G. Baron, G. Peytavin, L. Massias, F. Mentre, and R. Farinotti. 2003. Comparison of lithium concentrations in red blood cells and plasma in samples collected for TDM, acute toxicity, or acute-on-chronic toxicity. Eur. J. Clin. Pharmacol. 59:583-587.
4. Carmichael, J., K.L. Sugars, Y.P. Bao, and D.C. Rubinsztein. 2002. Glycogen synthase kinase-3β inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J. Biol. Chem. 277:33791-33798.
5. Coghlan, M.P., A.A. Culbert, D.A. Cross, S.L. Corcoran, J.W. Yates, N.J. Pearce, O.L. Rausch, G.J. Murphy, P.S. Carter, L. Roxbee Cox, et al. 2000. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7:793-803.
6. Coyle, J.T., and R.S. Duman. 2003. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron. 38:157-160.
7. Cuervo, A.M., L. Stefanis, R. Fredenburg, P.T. Lansbury, and D. Sulzer. 2004. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 305:1292-1295.
8. Dantuma, N.P., K. Lindsten, R. Glas, M. Jellne, and M.G. Masucci. 2000. Shortlived green fluorescent proteins for quantifying ubiquitin/ proteasomedependent proteolysis in living cells. Nat. Biotechnol. 18:538-543.
9. Gould, T.D., G. Chen, and H.K. Manji. 2002. Mood stabilizer psychopharmacology. Clin. Neurosci. Res. 2:193-212.
10. Harnett, W., and M.M. Harnett. 1993. Inhibition of murine B cell proliferation and down-regulation of protein kinase C levels by a phosphorylcholine-containing filarial excretory-secretory product. J. Immunol. 151:4829-4837.
11. Huntington's Disease Collaborative Research Group. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome. Cell. 72:971-983.
12. Ju, S., G. Shaltiel, A. Shamir, G. Agam, and M.L. Greenberg. 2004. Human 1-D-myo-inositol-3-phosphate synthase is functional in yeast. J. Biol. Chem. 279:21759-21765.
13. Kabeya, Y., N. Mizushima, T. Ueno, A.Yamamoto, T. Kirisako, T. Noda, E. Kominami, Y. Ohsumi, and T. Yoshimori. 2000. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 19:5720-5728.
14. Klionsky, D.J., and S.D. Emr. 2000. Autophagy as a regulated pathway of cellular degradation. Science. 290:1717-1721.
15. Kruger, R., W. Kuhn, T. Muller, D. Woitalla, M. Graeber, S. Kosel, H. Przuntek, J.T. Epplen, L. Schols, and O. Riess. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18:106-108.
16. Lubrich, B., and D. van Calker. 1999. Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? Neuropsychopharmacology. 21:519-529.
17. Manji, H.K., and R.H. Lenox. 1998. Lithium: a molecular transducer of mood-stabilization in the treatment of bipolar disorder. Neuropsychopharmacology. 19:161-166.
18. Manning, B.D., and L.C. Cantley. 2003. Rheb fills a GAP between TSC and TOR. Trends Biochem. Sci. 28:573-576.
19. Mizushima, N. 2004. Methods for monitoring autophagy. Int. J. Biochem. Cell Biol. 36:2491-2502.
20. Mizushima, N., A. Yamamoto, M. Matsui, T. Yoshimori, and Y. Ohsumi. 2004. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol. Biol. Cell. 15:1101-1111.
21. Moore, G.J., J.M. Bebchuk, J.K. Parrish, M.W. Faulk, C.L. Arfken, J. Strahl-Bevacqua, and H.K. Manji. 1999. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am. J. Psychiatry. 156:1902-1908.
22. Narain, Y., A. Wyttenbach, J. Rankin, R.A. Furlong, and D.C. Rubinsztein. 1999. A molecular investigation of true dominance in Huntington's disease. J. Med. Genet. 36:739-746.
23. Polymeropoulos, M.H., C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, A. Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, et al. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:2045-2047.
24. Ravikumar, B., R. Duden, and D.C. Rubinsztein. 2002. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 11:1107-1117.
25. Ravikumar, B., C. Vacher, Z. Berger, J.E. Davies, S. Luo, L.G. Oroz, F. Scaravilli, D.F. Easton, R. Duden, C.J. O'Kane, and D.C. Rubinsztein. 2004. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36:585-595.
26. Rubinsztein, D.C. 2002. Lessons from animal models of Huntington's disease. Trends Genet. 18:202-209.
27. Rubinsztein, D.C., J. Leggo, R. Coles, E. Almqvist, V. Biancalana, J.-J. Cassiman, K. Chotai, M. Connarty, D. Craufurd, A. Curtis, et al. 1996. Phenotypic characterisation of individuals with 30-40 CAG repeats in Huntington's disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am. J. Hum. Genet. 59:16-22.
28. Schmelzle, T., and M.N. Hall. 2000. TOR, a central controller of cell growth. Cell. 103:253-262.
29. Shaltiel, G., A. Shamir, J. Shapiro, D. Ding, E. Dalton, M. Bialer, A.J. Harwood, R.H. Belmaker, M.L. Greenberg, and G. Agam. 2004. Valproate decreases inositol biosynthesis. Biol. Psychol. 56:868-874.
30. Silverstone, P.H., B.M. McGrath, and H. Kim. 2005. Bipolar disorder and myoinositol: a review of magnetic resonance spectroscopy findings. Bipolar Disord. 7:1-10.
31. Webb, J.L., B. Ravikumar, J. Atkins, J.N. Skepper, and D.C. Rubinsztein. 2003. Alpha-synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278:25009-25013.
32. Williams, R.S., M. Eames, W.J. Ryves, J. Viggars, and A.J. Harwood. 1999. Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate. EMBO J. 18:2734-2745.
33. Williams, R.S., L. Cheng, A.W. Mudge, and A.J. Harwood. 2002. A common mechanism of action for three mood-stabilizing drugs. Nature. 417:292-295.
34. Wood, N.I., and A.J. Morton. 2003. Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. Brain Res. Bull. 61:375-383.
35. Wyttenbach, A., J. Swartz, H. Kita, T. Thykjaer, J. Carmichael, J. Bradley, R. Brown, M. Maxwell, A. Schapira, T.F. Orntoft, et al. 2001. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum. Mol. Genet. 10:1829-1845.
36. Wyttenbach, A., O. Sauvageot, J. Carmichael, C. Diaz-Latoud, A.P. Arrigo, and D.C. Rubinsztein. 2002. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet. 11:1137-1151.